PHASE-I STUDY OF N-(PHOSPHONACETYL)-L-ASPARTIC ACID (PALA)

1 January 1979

journal article
research article

Vol. 63 (11-1) , 1909-1912

Abstract

L-Aspartic acid (PALA), an inhibitor of aspartate transcarbamylase, was administered to 25 patients with advanced cancer by 10 min infusion daily on 5 consecutive days to determine the toxicity of PALA and to look for evidence of therapeutic effect. Planned dose escalations ranged from 100-1250 mg/m2 (daily dose). Nausea, vomiting and diarrhea were the most frequent toxic effects, with 3 of 6 patients treated at a daily dose of 1250 mg/m2 having severe diarrhea. Other toxic effects were encountered rarely and were not dose-limiting; these included mild leukopenia and rarely thrombocytopenia, rash, stomatitis and increases in SGOT [serum glutamic oxaloacetic transminase]. One patient with a widely metastatic carcinoid of unknown origin had an objective response lasting 6 wk.

This publication has 2 references indexed in Scilit:

EFFECTS OF N-(PHOSPHONACETYL)-L-ASPARTATE ON MURINE TUMORS AND NORMAL TISSUES INVIVO AND INVITRO AND RELATIONSHIP OF SENSITIVITY TO RATE OF PROLIFERATION AND LEVEL OF ASPARTATE-TRANSCARBAMYLASE
1978
ANTITUMOR ACTIVITY OF N-(PHOSPHONACETYL)-L-ASPARTIC ACID, A TRANSITION-STATE INHIBITOR OF ASPARTATE-TRANSCARBAMYLASE
1976